CE: PCSK9 Inhibitors: The Role of the Pharmacist in Identifying and Addressing the Clinical and Economic Barriers for the Treatment of Hyperlipidemia

Pharmacy Times, January 2021, Volume 89, Issue 1

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

EDUCATIONAL OBJECTIVES

At the completion of this activity, the participant will be able to:

  • Examine the pathogenesis, incidence, risk factors, and current standards of care for the treatment of hyperlipidemia
  • Explore the efficacy and safety data associated with the use of PCSK9 inhibitors and their clinical benefits in the treatment of hyperlipidemia
  • Discuss the current hyperlipidemia management guidelines from the American Heart Association and the American College of Cardiology
  • Identify the role of the pharmacist in patient education and recognizing and educating patients who may be ideal candidates or currently on PCSK9 inhibitors for the treatment of hyperlipidemia through motivational interviewing

FACULTY

Paul B. Shaw, PharmD, BCPS, BCCP

Clinical Pharmacy Specialist — Cardiology, Kaiser Permanente of Colorado, Clinical Assistant Professor – University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Lafayette, Colorado

TARGET AUDIENCE: Pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: December 18, 2020

EXPIRATION DATE: January 18, 2022

ESTIMATED TIME TO COMPLETE ACTIVITY: 2.5 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.